Latest news with #2022InducementPlan
Yahoo
2 days ago
- Business
- Yahoo
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, June 03, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ('Olema' or 'Olema Oncology', Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to 11 new employees to purchase an aggregate of 322,000 shares of the Company's common stock, effective as of June 2, 2025. These awards were approved by the Compensation Committee of Olema's Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date for such employee and the remainder vesting in 36 equal monthly installments over the following three years, subject to the employee being continuously employed by Olema as of such vesting dates. The stock options have a 10-year term and an exercise price of $4.38 per share, equal to the last reported sale price of the Company's common stock as reported by Nasdaq on June 2, 2025. The stock options are subject to the terms of the Olema Pharmaceuticals, Inc., 2022 Inducement Plan. Olema is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4). About Olema OncologyOlema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), currently in a Phase 3 clinical trial called OPERA-01. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical trial. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit Media and Investor Relations ContactCourtney O'KonekVice President, Corporate CommunicationsOlema Oncologymedia@ in to access your portfolio
Yahoo
3 days ago
- Business
- Yahoo
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on June 2, 2025, the Compensation Committee of Zentalis' Board of Directors granted non-qualified stock options to purchase an aggregate of 137,400 shares of the Company's common stock to four (4) newly hired employees. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to each such individual's entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4). The 2022 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Zentalis, or following a bona fide period of non-employment, as an inducement material to each such individual's entering into employment with Zentalis, pursuant to Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $1.28 per share, which is equal to the closing price of Zentalis' common stock on The Nasdaq Global Market on the date of grant. The stock options have a 10-year term and will vest over four years, with 25% of the options vesting on the first anniversary of the vesting commencement date and the remaining 75% of the options vesting in equal monthly installments over the three years thereafter. Vesting of the stock options is subject to the employees' continued service to Zentalis on each vesting date. About Zentalis PharmaceuticalsZentalis® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC). Azenosertib is being evaluated as a monotherapy and in combination across multiple tumor types in clinical trials and has broad franchise potential. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types. The Company is also leveraging its extensive experience and capabilities to translate its science to advance research on additional areas of opportunity for azenosertib outside PROC. Zentalis has operations in San Diego. For more information, please visit Follow Zentalis on X/Twitter at @ZentalisP and on LinkedIn at Contact:Aron Feingold, VP, IR & Corp Commsir@
Associated Press
01-03-2025
- Business
- Associated Press
Cardlytics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Cardlytics, Inc. (NASDAQ: CDLX) today announced that on February 26, 2025, the Compensation Committee of Cardlytics' Board of Directors granted an aggregate of 225,800 restricted stock units of Cardlytics to 18 newly hired employees. The restricted stock units were granted as material inducements to employment with Cardlytics in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Cardlytics, Inc. 2022 Inducement Plan (the '2022 Inducement Plan'). For all of the grant recipients, 50% of the restricted stock units shall vest on the first anniversary of the grant date, and the remaining 50% shall vest quarterly over the subsequent 12 months, subject to the employees' continuous service with Cardlytics through the vesting date. The restricted stock units are subject to the terms and conditions of the 2022 Inducement Plan. About Cardlytics Cardlytics (NASDAQ: CDLX) is a digital advertising platform. We partner with financial institutions to run their rewards programs that promote customer loyalty and deepen relationships. In turn, we have a secure view into approximately 1 of every 2 card-based transactions in the U.S., allowing us to see where and when consumers are spending their money. We use these insights to help marketers identify, reach, and influence likely buyers at scale, as well as measure the true sales impact of marketing campaigns. Headquartered in Atlanta, Cardlytics has offices in Menlo Park, Los Angeles, New York, and London. Learn more at SOURCE: Cardlytics, Inc. Copyright Business Wire 2025. PUB: 02/28/2025 04:05 PM/DISC: 02/28/2025 04:05 PM
Yahoo
31-01-2025
- Business
- Yahoo
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif. & BOSTON, January 31, 2025--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards on January 31, 2025. Two individuals were hired by Adicet in January 2025. In the aggregate, Adicet granted new hires non-qualified stock options to purchase 28,600 shares of Adicet's common stock with an exercise price of $0.89 per share, the closing price of Adicet's common stock as reported by Nasdaq on January 31, 2025. One-fourth of the shares underlying each employee's option will vest on the one-year anniversary of each recipient's start date and thereafter the remaining three-fourths of the shares underlying each employee's option will vest in thirty-six substantially equal monthly installments, such that the shares underlying the option granted to each employee will be fully vested on the fourth anniversary of the recipient's start date, in each case, subject to each such employee's continued employment with Adicet on such vesting dates. In addition, effective as of January 31, 2025, the board of directors approved an inducement award of non-statutory stock options to Julie Maltzman, M.D., Adicet's newly appointed Chief Medical Officer, to purchase 750,000 shares of Adicet's common stock with an exercise price of $0.89 per share, the closing price of Adicet's common stock as reported by Nasdaq on January 31, 2025. One-fourth of the shares underlying Dr. Maltzman's option will vest on the one-year anniversary of December 7, 2024 and thereafter the remaining three-fourths of the shares underlying the option will vest in thirty-six substantially equal monthly installments, such that the shares underlying the option granted to Dr. Maltzman will be fully vested on the fourth anniversary of December 7, 2024, subject to Dr. Maltzman's continued employment with Adicet on each such vesting date. The options are subject to the terms and conditions of the award agreement covering the grant. All of the above-described awards were granted outside of Adicet's stockholder-approved equity incentive plans pursuant to Adicet's 2022 Inducement Plan (the Inducement Plan), which was adopted by the board of directors in January 2022 and subsequently amended in January 2023. The awards were authorized by a majority of Adicet's independent directors or the compensation committee of the board of directors, which is comprised solely of independent directors, as a material inducement to the employees entering into employment with Adicet in accordance with Nasdaq Listing Rule 5635(c)(4). About Adicet Bio, Inc. Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of "off-the-shelf" gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at View source version on Contacts Adicet Bio, and Media ContactsInvestors: Anne Bowdidgeabowdidge@ Janhavi MohitePrecision Media: Kerry Beth Dalykbdaly@ Sign in to access your portfolio
